BioMedNewsBreaks — Jackson Acquisition Company II (NYSE: JACS.U) Announces Closing of IPO

Jackson Acquisition Company (NYSE: JACS.U) has closed its initial public offering of 23,000,000 units at $10.00 per unit. According to the announcement, the offering size reflects the full exercise of the underwriter’s over-allotment option. The units began trading on the New York Stock Exchange under the ticker symbol JACS.U on Dec. 10, 2024. Each unit consists of one Class A ordinary share and one right to receive one-tenth (1/10) of a Class A ordinary share upon the consummation of an initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on the NYSE under the symbols JACS and JACS.R, respectively. Roth Capital Partners acted as the sole manager for the offering.

To view the full press release, visit https://ibn.fm/9oV2L

About Jackson Acquisition Company II

The company, led by Chairman of the Board of Directors and Chief Executive Officer Richard L. Jackson, is a special purpose acquisition company formed for the purpose of effecting a merger, share

exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While it may pursue an initial business combination in any industry, the company intends to concentrate its search on businesses with a focus on healthcare services, healthcare technology or otherwise focused on the healthcare industry.

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN